Summary

A monoclonal antibody that blocks white blood cell adhesion to gut mucosal cells reduced the symptoms of moderate to severe ulcerative colitis in patients treated for 12 weeks in the randomized double-blind placebo-controlled TURANDOT trial. The antibody dose of 22.5 mg was most effective. No safety issues were evident.